Cephalon beats Street

Cephalon Inc. (NASDAQ:CEPH) report 4Q09 diluted adjusted EPS of $1.66, beating by $0.08 the Street's estimate of $1.58 and up 14% from $1.46 in 4Q08. Fourth quarter revenues were $575.1 million, above the Street's estimate of $572.5 million and up 6% from $540.1 million in 4Q08. For the year, Cephalon reported diluted adjusted EPS of $6.03, up 25% from $4.82 in 2008. Revenues for 2009 were up 11% to $2.2 billion.

The company introduced 1Q10 sales guidance of $575-$595 million and adjusted basic EPS of $1.60-$1.70. For 2010, Cephalon expects sales of $2.6-$2.7 billion and EPS of $6.80-$7. The 2010 estimates assume that the acquisition of generics company Mepha AG (Basel, Switzerland) closes April 1 (See BioCentury, Feb. 08, 2010). ...